KESIMPTA - How does MS develop

Prescribing information

Image

Image

How does MS develop?

KESIMPTA®▼ (ofatumumab) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.[1]

For full safety information, please refer to the KESIMPTA Summary of Product Characteristics (SmPC).[1]

MS is a complex, autoimmune condition defined by inflammation, demyelination and axonal damage in the CNS. This damage is caused by B-cells within the lymph nodes, which capture auto-antigens from neurons or their myelin sheaths and, upon presentation to T-cells, direct them to attack the body’s CNS tissue.[2,3]

To learn more about the pathogenesis of MS and the role of B-cells in the disease, watch this short video.



VIDEO

CNS, central nervous system; MS, multiple sclerosis; RMS, relapsing multiple sclerosis.

References:

1. KESIMPTA (ofatumumab) Summary of Product Characteristics.
2. Pender MP, et al. *Curr Allergy Asthma Rep* 2007;(4):285–292.
3. Archelos JJ, et al. *Ann Neurol* 2000;47:694–706.

Image

Safety profile

UK | January 2025 | 443403

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.
